StockData

Arvinas vs IDEAYA Biosciences

ARVN and IDYA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARVN and IDYA compare

IDEAYA Biosciences is the larger company, worth 6.6 times as much as Arvinas ($2.9B against $443M).

Arvinas keeps more of each dollar of sales as profit, with a net margin of 2.9% compared with −74.8% at IDEAYA Biosciences.

IDEAYA Biosciences scores higher on the StockData Score (9 against 8 for Arvinas), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARVNIDYA
Size and price
Market cap$443M$2.9B
Share price$6.77$30.36
Change, 1 year−33.1%−4.6%
Change, 5 years−91.4%27.5%
Beta (5Y)2.010.98
Employees246145
StockData Score
Total score89 (better)
Valuation score1 (better)0
Growth score11
Performance score3 (better)2
Health score36 (better)
Dividend score00
Valuation
P/E42.3×–
P/S1.4× (better)12.5×
P/B0.8× (better)2.4×
FCF yield−47.2%−3.9% (better)
Fair value–$29.50
Margin of safety–−2.9%
Growth
Revenue growth (TTM)−15.0%–
Revenue growth, 5Y average58.9%62.1% (better)
Profitability
Operating margin−5.7% (better)−92.7%
Net margin2.9% (better)−74.8%
FCF margin−65.9%−48.6% (better)
Return on equity1.6% (better)−16.2%
Return on invested capital–−51.9%
Financial health
Debt / equity0.00 (better)0.00
Current ratio7.9110.45 (better)
Altman Z-score0.6315.20 (better)
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions86.0%106%
Held by insiders7.8%0.83%
Insider net buying, 12 months−$1.2M$281K (better)
Short interest, % of float9.5%8.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.